Core Viewpoint - Coca-Cola is set to report its second-quarter financial results, with analysts expecting a revenue increase to $12.54 billion, up from $12.36 billion in the same quarter last year [1] Earnings Estimates - Analysts predict Coca-Cola will report quarterly earnings of 83 cents per share, a slight decrease from 84 cents in the previous year [3] - The company has consistently beaten earnings estimates, achieving this in five consecutive quarters and eight out of the last ten [3][2] Market Context - Coca-Cola's results come after PepsiCo's recent earnings report, which exceeded analyst expectations and raised full-year guidance [4][5] - The weak dollar is anticipated to positively impact Coca-Cola's earnings in key foreign markets, such as Latin America and Asia [6] Analyst Insights - Bank of America Securities analyst Bryan D. Spillane remains bullish on Coca-Cola, citing resilient growth and improving fundamentals [6] - Spillane has reiterated a Buy rating with a price target of $66, suggesting that Coca-Cola's strength is not fully reflected in its stock price [7] Key Items to Watch - Analysts will be focused on the potential impact of tariffs and the company's response to President Trump's comments about using real cane sugar in its beverages [10][8] - Coca-Cola may consider offering a version of its product with real cane sugar while maintaining its regular formula due to cost and logistics concerns [9] Stock Performance - Coca-Cola stock is currently trading at $70.08, reflecting a year-to-date increase of 13.3% [13] - The stock's performance is significant as it is a key holding in Warren Buffett's Berkshire Hathaway, which owns over 400 million shares [11][12]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 2% above guidance, with non-GAAP EPS also exceeding expectations [6][35] - Total direct-to-consumer revenue declined approximately 3%, while e-commerce revenue grew by 3% [6][39] - Gross margin decreased to 58.6%, down 280 basis points compared to the previous year [40][41] - EBIT for the quarter was $160 million, with an operating margin of 8.1% [41] Business Line Data and Key Metrics Changes - Calvin Klein's underwear and jeans categories saw a 25% increase in sales due to innovative product launches [9][60] - Tommy Hilfiger experienced a 3% revenue increase, driven by growth in EMEA and Americas [39] - Wholesale revenue increased by mid-single digits, benefiting from earlier shipments and the relaunch of Calvin Klein women's sportswear [6][15] Market Data and Key Metrics Changes - EMEA revenue grew by 4% in constant currency, with mid-single digit growth in wholesale [37] - Americas revenue increased by 7%, driven by high teens growth in wholesale [37] - Asia Pacific revenues declined by low teens on a reported basis, attributed to weaker consumer confidence [17][38] Company Strategy and Development Direction - The company is focused on executing the PVH Plus plan to strengthen brand performance and consumer engagement [6][33] - Plans to enhance product innovation and marketing efforts, particularly in Calvin Klein's underwear and denim categories [28][29] - The company is taking back licenses for Calvin Klein sportswear and jeans to improve brand control and execution [20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging macro environment, with weakened consumer sentiment and increased promotional levels [22][47] - The company remains committed to long-term growth in China despite current challenges [23] - Full-year revenue guidance is reaffirmed as flat to slightly up, but EPS guidance has been adjusted down due to macro pressures [27][49] Other Important Information - The company returned over $550 million to shareholders through share repurchases [36] - Inventory levels increased by 19% compared to the previous year, primarily due to strategic investments in core product categories [42] Q&A Session Summary Question: What gives confidence that both brands still have good momentum with consumers? - Management highlighted strong product innovation and marketing efforts that have driven significant growth in key categories despite macro challenges [58][60] Question: Can you provide details on the cost-out efforts and their timing? - Management discussed ongoing operational improvements and cost-saving initiatives that are expected to deliver significant benefits in the second half of the year [66][75] Question: How are tariffs impacting the business and what mitigation strategies are in place? - The company identified a $65 million unmitigated impact from tariffs and is working on optimizing sourcing and production costs to mitigate this effect [78][81]

Core Viewpoint - Dick's Sporting Goods is expected to provide more details regarding its acquisition of Foot Locker, Inc. during the upcoming first-quarter financial results announcement, with analysts closely monitoring the implications of this deal [1]. Earnings Estimates - Analysts anticipate Dick's Sporting Goods will report first-quarter revenue of $3.59 billion, an increase from $3.02 billion in the same quarter last year [1]. - The expected earnings per share for the first quarter is $4.34, up from $3.30 in the previous year [2]. Analyst Sentiment - Following the acquisition announcement, analysts have lowered their price targets for Dick's Sporting Goods stock, with Telsey analyst Joseph Feldman reducing the target from $250 to $220 while maintaining an Outperform rating [3]. - There is skepticism among investors regarding the acquisition, particularly due to Foot Locker's reliance on Nike, which constitutes approximately 60% of its sales [4]. Key Items to Watch - Analysts and investors will be focused on the impact of tariffs on Dick's Sporting Goods, as the company is expected to address this in its financial results [5][6]. - The company has initiated a five-year share buyback program of up to $3 billion, which could help alleviate concerns stemming from the acquisition and tariffs [7]. - Dick's Sporting Goods is also increasing its interest in trading cards, highlighted by a recent auction win for a rare baseball card valued at $1.1 million [7]. Stock Performance - As of the latest trading session, Dick's Sporting Goods stock rose by 3.92% to $173.81, with a year-to-date decline of approximately 24% [8].

Financial Data and Key Metrics Changes - Global revenue increased to $1.2 billion, with global service revenue up nearly $88 million or over 9% from the previous year [17] - Third quarter GAAP net income increased by over 6% to $407 million or $0.42 per diluted common share [22] - Global gross profit was approximately $552 million, an increase of $27 million or about 5%, with a gross margin percentage of 46% for the quarter [21] Business Line Data and Key Metrics Changes - Global unit sales increased by 1%, with a per business day increase of over 2% [10] - U.S. insurance unit volume decreased close to 1% year over year, while non-insurance U.S. unit volume growth outpaced that of the U.S. insurance business [11] - Blue Car services grew nearly 14% year over year, while dealer sales volume grew over 3% [12] Market Data and Key Metrics Changes - International segment unit sales grew by 6% in the quarter, with fee units increasing by 9% [12] - Global average selling prices (ASPs) increased by approximately 3% for the quarter, with U.S. insurance ASPs up over 2% [14] - Global inventory decreased nearly 10% from the year-ago period, with U.S. inventory down approximately 11% [14][15] Company Strategy and Development Direction - The company continues to invest in real estate infrastructure, technology, and operational readiness in anticipation of the 2025 storm season [8] - The acquisition of Hull Ranch in South Florida enhances the company's capacity to handle storm-related vehicle storage [7] - The company aims to enhance capabilities for both storm preparedness and day-to-day operations [9] Management's Comments on Operating Environment and Future Outlook - Management noted rising total loss frequency, which reached 22.8% in the first calendar quarter of 2025, up 100 basis points from last year [3] - The company anticipates an active storm season in 2025, similar to 2024, based on meteorological forecasts [6] - Management expressed confidence that cyclical trends regarding uninsured and underinsured drivers will eventually reverse [5] Other Important Information - Global purchased vehicle sales for the third quarter decreased approximately 2%, while gross profit from purchased vehicles decreased 60% [18] - Facility-related costs increased by $51 million or about 12%, reflecting ongoing investments in operational capacity [20] - The company has over $5.6 billion in liquidity, comprised of nearly $4.4 billion in cash and $1.3 billion in revolving credit capacity [23] Q&A Session Summary Question: Discussion on land assets and benefits for insurance salvage customers - Management emphasized the importance of physical storage and logistics for insurance companies and other sellers, viewing it as essential to their service offering [28] Question: Insights on the shift of insured versus uninsured motorists - Management noted cyclical trends in insurance coverage, with current conditions reflecting a similar downturn as seen during the global financial crisis [31] Question: Update on Purple Wave partnership and future investments - Management acknowledged the uncertain environment affecting Purple Wave but expressed confidence in the strategic fit and potential benefits for Copart [35] Question: Implications of trade policy and tariffs on business - Management highlighted the uncertainty created by tariffs on parts, which increases repair costs and may make total loss options more attractive [38] Question: Market share perspective and growth numbers - Management indicated that market share is influenced by the growth of individual insurance carriers and emphasized their commitment to delivering value to clients [46] Question: Trends in G&A spend and future expectations - Management clarified that the increase in G&A was primarily due to investments in the sales force and other minor platform services, without indicating a steady state number [64] Question: Legislative actions affecting storage fees and total loss thresholds - Management noted that capping storage fees could benefit insurance companies, while changes to total loss thresholds may not significantly distort insurance companies' decisions [72]

Financial Data and Key Metrics Changes - The company reported a net loss of $7.1 million for Q1 2025, an improvement from a net loss of $17.5 million in Q1 2024, driven by ongoing class of trade conversions and real estate rationalization efforts [23] - Adjusted EBITDA for Q1 2025 was $24.3 million, a 3% increase from $23.6 million in Q1 2024 [24] - Distributable cash flow decreased to $9.1 million in Q1 2025 from $11.7 million in Q1 2024, primarily due to higher cash interest expense and sustaining capital expenditures [24] Business Line Data and Key Metrics Changes - Retail segment gross profit increased by 16% to $63.2 million in Q1 2025 compared to $54.4 million in Q1 2024, driven by increases in both motor fuel and merchandise gross profit [8] - Wholesale segment gross profit declined by 1% to $26.7 million in Q1 2025, primarily due to a decline in fuel volume and rental income [17] - Inside sales on a same-site basis were down approximately 1.5% year over year, while inside sales excluding cigarettes declined by 1% [13] Market Data and Key Metrics Changes - Retail same-store fuel volume was approximately in line with the overall market, while same-store merchandise sales, excluding cigarettes, outperformed the market but were still below prior year results [7] - National gasoline demand was down approximately 4% for the quarter, reflecting broader market trends [10] - The company’s retail fuel margin increased by 10% year over year to 33.9 cents per gallon in Q1 2025, compared to 30.8 cents per gallon in Q1 2024 [8] Company Strategy and Development Direction - The company continues to focus on converting lessee dealer sites to company-operated retail sites, increasing overall retail site count by 64 sites year over year [16] - The strategy includes optimizing class of trade operations and ongoing real estate rationalization to generate additional capital for strategic investments [31] - The company aims to grow motor fuel and merchandise gross profit and overall segment profitability through site conversions and increased retail exposure [16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging start to the year due to subdued demand for fuel and merchandise, significant winter weather, and inflationary pressures [21] - Despite these challenges, management expressed optimism about the execution of their strategy and the potential for improved performance in the upcoming summer driving season [22] - The company remains focused on maintaining a strong balance sheet and generating value for unitholders [32] Other Important Information - The company divested seven sites for $8.6 million in proceeds during the quarter, with expectations to continue this momentum throughout 2025 [21] - Operating expenses for the retail segment increased by approximately 20% year over year, primarily due to an increase in average site count [26] - The company spent a total of $10.1 million on capital expenditures in Q1 2025, with $7.4 million allocated to growth-related projects [28] Q&A Session Summary - There were no questions during the Q&A session, and the call concluded with closing comments from the CEO [34][35]

Core Viewpoint - Masimo Corporation reported strong financial results for the first quarter of 2025, with significant year-over-year growth in adjusted earnings per share (EPS) and revenues, indicating robust performance in its healthcare segment and a positive outlook for the year ahead [1][2][12]. Financial Performance - Adjusted EPS for Q1 2025 was $1.36, a 56.3% increase year over year, surpassing the Zacks Consensus Estimate by 9.7% [1] - GAAP EPS for the quarter was 86 cents, reflecting a 45.8% increase from 59 cents in the same period last year [1] - Revenues reached $372 million, up 9.5% year over year, exceeding the Zacks Consensus Estimate by 1.3% [2] - At constant exchange rates, revenues were $375.2 million, marking a 10.5% increase year over year [2] Revenue Breakdown - Revenue excluding related party revenues was $340.2 million, up 10.1% year over year, while related party revenues were $31.8 million, up 3.9% year over year [4] - Healthcare revenues totaled $371 million, a 9.2% increase on a reported basis and 10% at constant exchange rates year over year [5] - Consumable and service revenues grew by 8%, while capital equipment and other revenues surged by 32% year over year [5] Margin Analysis - Gross profit increased by 13.3% year over year to $234 million, with a gross margin expansion of 207 basis points to 62.9% [6] - Total adjusted operating profit was $80.7 million, reflecting a 51.9% increase from the previous year, with an adjusted operating margin of 21.7%, up 606 basis points [7] Financial Position - Cash and cash equivalents at the end of Q1 2025 were $130.8 million, up from $123.6 million at the end of 2024 [9] - Long-term debt decreased to $636 million from $714.3 million at the end of 2024 [9] - Net cash provided by operating activities was $37.9 million, slightly down from $38.6 million a year ago [9] Guidance - For 2025, total revenues are expected to be in the range of $1,500 million to $1,530 million, representing an 8-11% increase at constant exchange rates from 2024 [10] - Adjusted EPS for 2025 is projected to be between $5.30 and $5.60, reflecting a growth of 22-29% from 2024 figures [11] Strategic Developments - Masimo has entered into an agreement to sell its Sound United consumer audio business to HARMAN International, focusing on its core professional healthcare segment [13] - Management anticipates an increasing impact of tariffs each quarter for the remainder of the year, which may affect future performance [14]

Financial Data and Key Metrics Changes - The company reported total revenues of $898 million for Q1 2025, with a year-over-year growth of 9% for Xywav and 10% for Epidiolex [8][29][30] - Adjusted net income was impacted by a $172 million charge related to Xyrem antitrust litigation settlements, reducing GAAP and non-GAAP EPS by $2.38 and $2.34 respectively [31][36] - The company affirmed its total revenue guidance for 2025, maintaining a range of $4.15 billion to $4.4 billion, representing a 5% year-over-year growth at the midpoint [36][38] Business Line Data and Key Metrics Changes - The neuroscience portfolio, led by Xywav, generated approximately $431 million in total revenue, with Xywav net product sales at $345 million, a 9% increase year-over-year [12][8] - Epidiolex had net product sales of approximately $218 million, reflecting a 10% increase year-over-year, driven by underlying demand and favorable U.S. payer mix [15][17] - Oncology product sales were approximately $94 million, a decrease of 8% year-over-year, primarily due to changes in pediatric treatment protocols affecting Rylase sales [18][30] Market Data and Key Metrics Changes - The company reported approximately 14,600 active Xywav patients, with a net increase of 450 patients compared to Q4 2024, indicating strong market penetration [14] - The idiopathic hypersomnia market saw a 39% increase in patient adds over the last twelve months, reflecting successful disease education campaigns [90] Company Strategy and Development Direction - The company is focused on expanding its oncology portfolio, with a supplemental new drug application submitted for Zepzelca to include first-line maintenance therapy in extensive-stage small cell lung cancer [9][21] - The acquisition of Chimerix is expected to enhance the company's presence in rare oncology and provide a near-term commercial opportunity with doravaprone [10][25] - The company aims to maintain financial flexibility and operational excellence while navigating potential tariff impacts [11][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the top-line revenue guidance and highlighted the potential for growth in the oncology portfolio with upcoming regulatory approvals [11][36] - The company remains optimistic about the blockbuster potential of Epidiolex and the growth trajectory of Xywav, despite near-term headwinds in oncology [9][17] Other Important Information - The company is advancing its R&D pipeline, with key trials expected to read out in the second half of 2025, including the Horizon GEA-one Phase III trial [10][22] - The company has sufficient inventory to meet its 2025 needs, mitigating potential impacts from tariffs [33][34] Q&A Session Summary Question: Supply chain and Xywav production capabilities - The company confirmed it has a U.S. supplier for Xywav with sufficient capacity to meet U.S. needs, which could mitigate tariff exposure [46][47] Question: Manufacturing footprint and potential tariff impacts - The company has multiple manufacturing locations, including a U.S. CMO and facilities in Ireland and the UK, providing flexibility in response to potential tariffs [51][52] Question: Zepzelca's growth trajectory amidst competition - Management expects Zepzelca to return to growth, driven by upcoming data presentations and potential inclusion in treatment guidelines [59][60] Question: Chimerix acquisition rationale - The acquisition aligns with the company's strategy to address unmet medical needs in oncology and is expected to provide a near-term commercial opportunity [69][70] Question: Rylase growth in the adolescent and young adult market - Management indicated that education efforts are ongoing, and they expect normalization of Rylase revenues in the second quarter of 2025 [74][75]

Financial Data and Key Metrics Changes - Consolidated net revenue increased by 8.8% on a constant currency basis for the quarter, driven by 12% volume growth, particularly in North America [7][15] - Adjusted EBITDA declined by 7.8% for the quarter, including a non-cash impact of the Amazon warrants, which contributed a 4.2% headwind to reported figures [10][18] - Overall profitability was negatively impacted by increased input costs and lower sales volume in Europe and Asia Pacific [11][12] Business Line Data and Key Metrics Changes - North America saw sales up by 33% and volumes up more than 40% compared to Q1 2024, driven by strong growth in enterprise accounts [7][15] - Europe and Asia Pacific combined revenue decreased by 6% on a constant currency basis, primarily due to lower PTS volumes in March [15] - Automation sales in EMEA were in line with expectations, with a forecast for meaningful growth in 2025 [15] Market Data and Key Metrics Changes - North America exhibited robust growth, while Europe experienced a deterioration in activity, particularly in March [9][33] - April showed stabilization in Europe, with volumes up compared to the prior year, but overall activity was still weaker than at the start of the year [10][34] - Japan was highlighted as a strong market within Asia Pacific, while Southeast Asia and Australia showed mixed performance [35][36] Company Strategy and Development Direction - The company is focused on driving volumes, winning market share, reducing structural costs, and maximizing cash flow [13][29] - There is an emphasis on deepening relationships with major e-commerce and retail players to support growth in North America [8] - The company is taking steps to mitigate tariff impacts by evaluating alternative suppliers and refurbishing existing machines [25][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to weather disruptions from global trade discussions due to its diverse geographic presence [6][29] - There is cautious optimism regarding potential growth in Europe, influenced by legislative changes and stimulus measures [34] - The company remains confident in achieving a 50% growth rate in automation despite potential delays due to macroeconomic factors [42][44] Other Important Information - The company invested over $10 million in additional paper inventory to mitigate lead time disruptions [19] - The impact of the Amazon warrants will continue to create non-cash decreases in reported revenue figures [22][23] - The company is implementing structural cost reductions of $8 million to improve its financial profile [18] Q&A Session Summary Question: Insights on EMEA and APAC performance in March and April - Management noted that Southern Europe performed better than Northern Europe, with some stabilization observed in April [33][34] Question: Expectations for automation project timelines - Management indicated that while some projects may slip between quarters, they remain confident in achieving significant growth in automation [40][42] Question: Outlook on gross margin improvements - Management expects gross margin to improve from Q1 to Q2, with further improvements anticipated in Q3 and Q4 as cost initiatives take effect [47][48] Question: Details on cost reduction actions - Management highlighted operational efficiencies, better planning, and structural cost reductions as key areas for improving margins [50][54]

Financial Data and Key Metrics Changes - The company experienced a decline in overall market categories, with average declines in the low single digits during the third quarter [14][22] - Despite the challenges, the company maintained market shares and achieved its tenth consecutive quarter of gross margin expansion [9][10] - The gross margin for the fourth quarter is expected to be around 44%, consistent with the annual average of approximately 44.5% [40] Business Line Data and Key Metrics Changes - The household products segment faced significant competitive pressure, leading to a decline in sales, particularly in the Glad brand due to increased promotional activity [96][100] - The cleaning category showed resilience, with the company growing market share despite overall category declines [86][111] - The cat litter segment is competitive, but the company has introduced innovations that are performing well in the market [100][101] Market Data and Key Metrics Changes - Consumer sentiment weakened significantly in the second half of the third quarter, impacting shopping behaviors and leading to lower-than-expected sales [8][9] - Retailers are adjusting their inventory levels, which has resulted in some destocking, particularly in the household segment [41][44] - The company noted a shift in consumer spending towards essentials and larger purchases, impacting discretionary categories [17][78] Company Strategy and Development Direction - The company aims to continue delivering organic sales growth and strong earnings growth while navigating a challenging consumer environment [10][120] - There is a focus on innovation and maintaining a balanced portfolio that caters to both premium and value-seeking consumers [55][111] - The company is actively managing its supply chain and pricing strategies to mitigate the impact of tariffs and maintain margins [32][70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of their essential product categories despite current economic uncertainties [9][23] - The outlook for fiscal year 2025 anticipates continued challenges, with organic sales growth expected to be muted [27][92] - The company is closely monitoring consumer behavior and market dynamics to adapt its strategies accordingly [23][120] Other Important Information - The company is preparing for an ERP transition, which is expected to enhance operational efficiency and inventory management [61][65] - There is a wide range in the sales outlook due to the volatility in consumer demand and retailer inventory adjustments [62][66] Q&A Session Summary Question: What is driving the category weakness? - Management noted that while categories are traditionally resilient, recent macroeconomic uncertainties have led to a low single-digit decline in sales [14][22] Question: How should we think about organic sales growth in the long term? - The company expects organic sales growth to be suppressed in the near term but anticipates a return to normal category growth over time [27][28] Question: What is the expected impact of tariffs on gross margin? - The anticipated gross impact from tariffs is around $100 million annually, with efforts underway to mitigate this through various strategies [31][32] Question: Can you provide insights on promotional activity by category? - Promotional activity has normalized overall, but some categories, like Glad, are experiencing higher promotional pressures due to competitive actions [50][51] Question: How is the ERP transition expected to impact sales? - The ERP transition is expected to lead to a build-up of inventory, which could translate into growth in the following quarters [65][66] Question: What is the company's approach to M&A in the current environment? - The company remains focused on strengthening its core business while exploring opportunities for portfolio improvement through M&A [120]

Financial Data and Key Metrics Changes - Net sales for Q1 2025 were approximately $585 million, representing a 4.2% decline from $611 million in Q1 2024. On a currency neutral basis, this reflects a 1.5% year-over-year decrease, primarily driven by lower sales in the Life Science Group [12][13] - Q1 reported GAAP gross margin was 52.3%, down from 53.4% in Q1 2024, mainly due to increased SG&A expenses [14] - Q1 operating income was approximately $24 million, or 4% of sales, compared to $45 million, or 7.3% of sales in Q1 2024, driven by higher restructuring costs [15] - GAAP net income for Q1 2025 was $71 million, or $2.54 diluted earnings per share [18] Business Line Data and Key Metrics Changes - Life Science Group sales in Q1 2025 were $229 million, down 5.4% on a reported basis and 3.5% on a currency neutral basis, reflecting ongoing softness in the biotech and academic research market [13] - Clinical Diagnostics Group sales were approximately $357 million, a decrease of 3.2% on a reported basis, with increased demand for quality control products offset by lower diabetes testing revenue [14] Market Data and Key Metrics Changes - In Diagnostics, solid demand was shown, offsetting reimbursement reductions in China with nearly 3% growth in the rest of the world [9] - Currency neutral sales decreased in Asia Pacific, partially offset by increased sales in EMEA and The Americas [14] Company Strategy and Development Direction - The company continues to prioritize bringing innovative products to customers, with several key menu expansions launched in Q1 [6][7] - The acquisition of Stila Technology is on track for closing by the end of Q3 2025, expanding offerings in the digital PCR segment [10] - The company is focused on mitigating tariff impacts through surcharges, pre-positioning inventory, and regionalizing supply chains [9][24] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging macro environment with academic market headwinds due to government funding and global trade disruptions [6] - The company expects total currency neutral revenue to decline by approximately 1% to 1.5% for 2025, reflecting softer academic research funding and reduced demand from biotech customers [21][22] - Management remains optimistic about long-term growth opportunities in life science and diagnostics despite current challenges [28][29] Other Important Information - The company generated $130 million in net cash from operating activities in Q1 2025, compared to $70 million in Q1 2024 [19] - Free cash flow for Q1 2025 was $96 million, up from $30 million in Q1 2024, with a full-year target of approximately $310 million to $330 million for 2025 [19][20] Q&A Session Summary Question: Can you discuss the impact of tariffs and mitigation efforts? - Management acknowledged the significant impact of tariffs on U.S. products shipped to China and Europe, and discussed actions such as surcharges and pre-positioning inventory to mitigate these effects [33][35][36] Question: What is the current state of academic funding? - Management noted a 28% reduction in overall funding and indicated that while consumables remained strong, instrument sales experienced softness [38][41] Question: How does the growth gap between consumables and equipment look? - Management indicated a deterioration in instrument sales, down about 10% sequentially, while consumables held up well [46][70] Question: What is the company's capital allocation strategy? - Management expressed interest in pursuing larger inorganic opportunities while continuing stock buybacks, indicating a strong balance sheet [64][65] Question: Can you provide an update on the Stila acquisition? - Management reported positive feedback from teams regarding the Stila platform and noted excitement about its potential applications [76][77]